What were the main drivers of revenue growth in the second quarter of 2021?

Revenue growth was primarily driven by the strong performance of BMY's key in-line products, particularly within the hematology and oncology segments, as well as continued uptake of recently launched products.

How did R&D investments impact the financial results?

Significant R&D investments are crucial for BMY's long-term strategy. While these investments represent an outflow, they are vital for developing new therapies and advancing the pipeline, which is expected to drive future revenue and profitability.

What is the company's outlook on returning capital to shareholders?

Bristol Myers Squibb continued its share repurchase program and maintained its dividend payments, reflecting a balanced approach to capital allocation that includes reinvesting in the business and providing returns to shareholders.

Are there any significant legal proceedings or risks mentioned in the filing?

The filing acknowledges ongoing legal proceedings and updates the risk factors section. Investors should refer to Item 1 (Legal Proceedings) and Item 1A (Risk Factors) for detailed information on potential impacts to the company's operations and financial condition.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q2 FY2021

Summary

Bristol Myers Squibb (BMY) reported its financial results for the second quarter ended June 29, 2021, demonstrating continued execution on its strategic priorities. The company achieved significant revenue growth, driven by its key products, and maintained a strong financial position. Investors should note the company's progress in advancing its pipeline and its commitment to returning value to shareholders through share repurchases and dividends, balanced with ongoing investments in research and development.

Financial Highlights

57 data points

Beta

Revenue

$11.70B

0.8% Gross Margin

Net Income

$1.05B

0.1% Net Margin

EPS (Diluted)

$0.47

Total Assets

$110.80B

Cash & Equivalents

$11.02B

Free Cash Flow

$2.85B

Financial Statements

Beta

Revenue	$11.70B
Cost of Revenue	$2.45B
Gross Profit	$9.25B
R&D Expenses	$2.48B
SG&A Expenses	$1.88B
Operating Expenses	$10.15B
Interest Expense	$330.00M
Net Income	$1.05B
EPS (Basic)	$0.47
EPS (Diluted)	$0.47
Shares Outstanding (Basic)	2.23B
Shares Outstanding (Diluted)	2.25B

Key Highlights

1Revenue increased compared to the prior year period, primarily driven by strong performance in key therapeutic areas and products.
2The company maintained a solid cash flow from operations, indicating efficient business management and the ability to fund ongoing initiatives.
3Significant investments in Research and Development (R&D) were made, underscoring BMY's commitment to innovation and future growth through pipeline advancement.
4The company continued its share repurchase program, demonstrating confidence in its valuation and a commitment to returning capital to shareholders.
5Net income and earnings per share (EPS) showed a positive trend, reflecting effective cost management and revenue growth.
6BMY highlighted progress in clinical trials and regulatory submissions for its pipeline assets, suggesting potential future revenue streams.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2021

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions